MicroPort® NeuroTech Attends CSA & TISC 2017

Beijing, China – From June 23 to June 25, MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort® NeuroTech") attended the Third Annual Scientific Session of Chinese Stroke Association & Tiantan International Stroke Conference 2017 ("CSA & TISC 2017") held in Beijing. Domestic and international experts, scholars and clinicians from the field of cerebrovascular diseases were gathered together to share viewpoints regarding the current situation and future development of the treatment of stroke and other related diseases.
Aside from lectures and speeches, the conference for the first time included a debate session. During the Tianhai Forum on June 24, representatives from Tiantan Hospital and Changhai Hospital debated over the treatment of acute aortic occlusion of stroke, which offered inspirational ideas to experts in attendance.
In the session of cerebral aneurysm interventional treatment, Professor Yuxiang Gu of Huashan Hospital of Fudan University shared the clinical experience of physicians in Huashan Hospital in using WILLIS® Intracranial Stent Graft System ("WILLIS®"). Professor Gu said, WILLIS® offers easy operation for physicians and excellent treatment effect for patients with intracranial aneurysm. The outstanding clinical performance of WILLIS® was highly praised by the attendees. Researched and developed independently by MicroPort® NeuroTech, WILLIS® obtained the regulatory approval from China Food and Drug Administration in 2013. It is the first stent graft system indicated for the treatment of intracranial aneurysms that has gained market approval in China, and also the first medical device to achieve complete vascular reconstruction in China. WILLIS® vascular reconstruction achieves complete occlusion, and unlike traditional treatment using stent-assisted coil embolization, WILLIS effectively shunts the blood flow and keeps it off of the aneurysm wall.
According to statistics, China has the highest occurrence rate of stroke in the world and in particular its prevalence among adults aged 40 and above reaches 2%. There are around 2.5 million new cases of stroke in China every year. As many as 11.1 million Chinese people are now suffering from stroke which leads to 1.6 million deaths annually. MicroPort® NeuroTech Zhiyong Xie said: "MicroPort® NeuroTech is dedicated to developing innovative solutions for cerebrovascular diseases. We will provide more high-end medical devices by constant innovation to benefit patients with cerebrovascular disease.